Department of Psychiatry, Beitou Armed Forces Hospital, Beitou, Taipei, Taiwan (R.O.C.) Correspondence: Chih-Sung Liang, M.D.; e-mail: luke_and_tina{at}yahoo.com.tw To the Editor: We hereby present a female patient with schizophrenia participating in a clinical trial who experienced a manic episode during a switch from risperidone to paliperidone.Case Report "Ms. C," a 62-year-old, Chinese, postmenopausal woman, had a 32-year history of schizophrenia. She had been hospitalized numerous times for failure to respond to traditional antipsychotics. In 2004, Ms. C began to receive risperidone and subsequently achieved a stable condition. Ms. C was admitted to our ward in 2006. Eighteen months later, while psychiatrically stable on risperidone 2 mg/day, she agreed to participate in an open-label paliperidone trial. Hence, risperidone was discontinued, and paliperidone 3 mg/day was started. Over the subsequent week, she started displaying progressively worsening manic symptoms, including euphoria, distractibility, racing thoughts, reduced need for sleep, hyperactivity, and pressured speech. Notably, these symptoms had not been reported before. There was no evidence of exacerbated psychosis, akathisia, delirium, or catatonia. Because of this adverse drug reaction (ADR), after 10 days of treatment with paliperidone, we decided to terminate Ms. C's participation in this study, and risperidone 2 mg/day was restarted, with
Manic Symptoms During a Switch From Risperidone to Paliperidone: A Case Report
Abstract
Department of Psychiatry, Beitou Armed Forces Hospital, Beitou, Taipei, Taiwan (R.O.C.) Correspondence: Chih-Sung Liang, M.D.; e-mail: luke_and_tina{at}yahoo.com.tw To the Editor: We hereby present a female patient with schizophrenia participating in a clinical trial who experienced a manic episode during a switch from risperidone to paliperidone.Case Report "Ms. C," a 62-year-old, Chinese, postmenopausal woman, had a 32-year history of schizophrenia. She had been hospitalized numerous times for failure to respond to traditional antipsychotics. In 2004, Ms. C began to receive risperidone and subsequently achieved a stable condition. Ms. C was admitted to our ward in 2006. Eighteen months later, while psychiatrically stable on risperidone 2 mg/day, she agreed to participate in an open-label paliperidone trial. Hence, risperidone was discontinued, and paliperidone 3 mg/day was started. Over the subsequent week, she started displaying progressively worsening manic symptoms, including euphoria, distractibility, racing thoughts, reduced need for sleep, hyperactivity, and pressured speech. Notably, these symptoms had not been reported before. There was no evidence of exacerbated psychosis, akathisia, delirium, or catatonia. Because of this adverse drug reaction (ADR), after 10 days of treatment with paliperidone, we decided to terminate Ms. C's participation in this study, and risperidone 2 mg/day was restarted, with
Loading next page...
If you're having problem loading pages
Try our single-page mode to load one page at a time
Preview Only. This article cannot be rented because we do not currently have permission from the publisher.
/lp/american-psychiatric-publishing-inc-journal/manic-symptoms-during-a-switch-from-risperidone-to-paliperidone-a-case-Qd2G8HKijh
Welcome to DeepDyve! Rent Premier Research Articles and Save Up to 90%
Preview Only
Manic Symptoms During a Switch From Risperidone to Paliperidone: A Case Report
Yang, Fei-Wen; Liang, Chih-Sung
Follow Journal of Neuropsychiatry & Clinical Neurosciences
, Volume 23 (3): E29
American Psychiatric Publishing, Inc (Journal) – Aug 1, 2011
More Info
More Like This Article
View All dataSource[]=actageo&dataSource[]=aspet&dataSource[]=aaos&dataSource[]=aacc&dataSource[]=aacr&dataSource[]=aea&dataSource[]=aip&dataSource[]=ajnr&dataSource[]=ams&dataSource[]=aps_physical&dataSource[]=appi_book&dataSource[]=appi_journal&dataSource[]=apha&dataSource[]=asip&dataSource[]=asm&dataSource[]=asn&dataSource[]=aspb&dataSource[]=avs&dataSource[]=annual_reviews&dataSource[]=arxiv&dataSource[]=acm&dataSource[]=berghahn&dataSource[]=cabi&dataSource[]=clinical_trials&dataSource[]=dailymed&dataSource[]=degruyter&dataSource[]=du_press&dataSource[]=esa&dataSource[]=eu_press&dataSource[]=elsevier&dataSource[]=emerald&dataSource[]=ejtr&dataSource[]=emea&dataSource[]=epo&dataSource[]=faseb&dataSource[]=gsa&dataSource[]=health_affairs&dataSource[]=hindawi&dataSource[]=imanager&dataSource[]=imedpub&dataSource[]=informa_healthcare&dataSource[]=informs&dataSource[]=iop&dataSource[]=iucr&dataSource[]=iospress&dataSource[]=jbjs&dataSource[]=leftcoast&dataSource[]=lu_press&dataSource[]=mesharpe&dataSource[]=mary_ann_liebert&dataSource[]=medline&dataSource[]=mit_press&dataSource[]=nature&dataSource[]=oxford&dataSource[]=pier_professional&dataSource[]=pnas&dataSource[]=portlandpress&dataSource[]=psyc_articles&dataSource[]=psyc_books&dataSource[]=psyc_critiques&dataSource[]=plos_journal&dataSource[]=pubmed_central&dataSource[]=rsna&dataSource[]=rockefeller&dataSource[]=rcn&dataSource[]=ria&dataSource[]=rsc&dataSource[]=sage&dataSource[]=spie&dataSource[]=springer_journal&dataSource[]=springer&dataSource[]=taylor_francis&dataSource[]=aps&dataSource[]=the_scientist&dataSource[]=uc_press&dataSource[]=uspto_abstract&dataSource[]=wiley&dataSource[]=pct
© 2012 DeepDyve, Inc. All rights reserved.
Terms of Service | Privacy Policy
